{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:23:56Z","timestamp":1768321436127,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12969-019-0364-z","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T11:03:51Z","timestamp":1566471831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7203-6307","authenticated-orcid":false,"given":"Navita L.","family":"Mallalieu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunethra","family":"Wimalasundera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Douglass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada Calvo","family":"Penades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Cuttica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Iko","family":"Huppertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rik","family":"Joos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Milojevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margalit","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Schikler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamas","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carine","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"key":"364_CR1","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385\u201395.","journal-title":"N Engl J Med"},{"key":"364_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3389\/fphar.2016.00467","volume":"7","author":"G Giancane","year":"2016","unstructured":"Giancane G, Minoia F, Davi S, Bracciolini G, Consolaro A, Ravelli A. IL-1 inhibition in systemic juvenile idiopathic arthritis. Front Pharmacol. 2016;7:467.","journal-title":"Front Pharmacol"},{"key":"364_CR3","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"364_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/AHMT.S109495","volume":"8","author":"S Grevich","year":"2017","unstructured":"Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther. 2017;8:125\u201335.","journal-title":"Adolesc Health Med Ther"},{"key":"364_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/1759720X12455960","volume":"4","author":"S Yokota","year":"2012","unstructured":"Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012;4:387\u201397.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"364_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1586\/eci.10.41","volume":"6","author":"S Yokota","year":"2010","unstructured":"Yokota S, Kishimoto T. Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2010;6:735\u201343.","journal-title":"Expert Rev Clin Immunol"},{"key":"364_CR7","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/art.1780340912","volume":"34","author":"F de Benedetti","year":"1991","unstructured":"de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34:1158\u201363.","journal-title":"Arthritis Rheum"},{"key":"364_CR8","first-page":"71","volume":"4","author":"M Murakami","year":"2012","unstructured":"Murakami M, Tomiita M, Nishimoto N. Tocilizumab in the treatment of systemic juvenile idiopathic arthritis. Open Access Rheumatol. 2012;4:71\u20139.","journal-title":"Open Access Rheumatol"},{"key":"364_CR9","unstructured":"Actemra\u00ae (tocilizumab) injection, for intravenous or subcutaneous use. South San Francisco: Genentech, Inc.; 2019. \n                    https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13\n                    \n                  ."},{"key":"364_CR10","unstructured":"RoActemra 162 mg solution for injection in pre-filled syringe. Welwyn Garden City. In: UK: Roche products limited; 2019. \n                    https:\/\/www.medicines.org.uk\/emc\/product\/9086\/smpc\n                    \n                  ."},{"key":"364_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3899\/jrheum.120386","volume":"40","author":"RA Russo","year":"2013","unstructured":"Russo RA, Katsicas MM. Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome. J Rheumatol. 2013;40:329\u201334.","journal-title":"J Rheumatol"},{"key":"364_CR12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/0091270009350623","volume":"50","author":"N Frey","year":"2010","unstructured":"Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010;50:754\u201366.","journal-title":"J Clin Pharmacol"},{"key":"364_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/17425255.2018.1482278","volume":"14","author":"P Malik","year":"2018","unstructured":"Malik P, Edginton A. Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opin Drug Metab Toxicol. 2018;14:585\u201399.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"364_CR14","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.intimp.2008.07.002","volume":"8","author":"Y Uchiyama","year":"2008","unstructured":"Uchiyama Y, Yoshida H, Koike N, Hayakawa N, Sugita A, Nishimura T, et al. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int Immunopharmacol. 2008;8:1595\u2013601.","journal-title":"Int Immunopharmacol"},{"key":"364_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism\/American College of Rheumatology\/Paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheum. 2016;68:566\u201376.","journal-title":"Arthritis Rheum"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0364-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-019-0364-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0364-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T23:11:17Z","timestamp":1597965077000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-019-0364-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["364"],"URL":"https:\/\/doi.org\/10.1186\/s12969-019-0364-z","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,22]]},"assertion":[{"value":"7 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice and was approved by the appropriate institutional review boards and\/or ethics committees. Written informed consent to participate in the study was obtained from the patients\u2019 parents or legal guardians.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NLM \u2013 Employee of Roche, owns shares in Roche.SW \u2013 Employee of Roche.JCH \u2013 Employee of Roche, owns share in Roche.WD \u2013 Employee of Roche, owns shares in Roche.CWells \u2013 Employee of Roche, owns shares in Roche.ICP \u2013 Research grants to institution from Roche.RC \u2013 Consultant and speaker for Roche, Novartis, Lilly, GlaxoSmithKline, Bristol Myers Squibb, Janssen.H-IH \u2013 None.RJ \u2013 None.YK \u2013 Salary support from CARRA; research grant from Genentech.DM \u2013 None.MR \u2013 None.KS \u2013 Research grant support from SOBI and CARRA.TC \u2013 None.CWouters \u2013 Research grants to institution from GlaxoSmithKline, Pfizer, Roche","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}